Eli Lily and Boehringer Ingelheim’s (BI) Jardiance (empagliflozin) Shows to Increase Life Span in Adults with T2D and Cardiovascular Disorders

Shots:

• Lily and BI reports results of EMPA-REG OUTCOME trial assessing Jardiance (10/25 mg qd) vs PBO, from 42 countries in 7,020 patients with T2D at high risk for cardiovascular events
• EMPA-REG OUTCOME results: mean survival @age 45 yrs. (32.1 yrs vs 27.6yrs); @age 50,60,70 & 80yrs. (3.1,2.5, 2,1 yrs.)
• Jardiance is a prescription drug indicated to lower blood sugar & reduce the risk of cardiovascular death in adults with T2D. In 2011, Eli Lily & BI entered into a collaboration agreement to jointly develop Jardiance for T2D

Click here to read full press release/ article | Ref: Eli Lily | Image: Boehringer Ingelheim